Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30425562 | 0.92 | HDAC6 (0.46) | HDAC6GSK3BDYRK1ANAMPTHDAC1 | |
| SCHEMBL25386481 | 0.92 | HDAC6 (0.46) | HDAC6GSK3BDYRK1ANAMPTHDAC1 | |
| SCHEMBL25215221 | 0.90 | NAMPT (0.45) | HDAC6GSK3BDYRK1ANAMPTHDAC1 | |
| SCHEMBL26226766 | 0.85 | NAMPT (0.53) | HDAC6NAMPTHDAC1 | |
| SCHEMBL25267691 | 0.85 | HDAC6 (0.49) | HDAC6NAMPTHDAC1 | |
| SCHEMBL30424923 | 0.85 | HDAC6 (0.49) | HDAC6NAMPTHDAC1 | |
| SCHEMBL25250825 | 0.85 | HDAC6 (0.44) | HDAC6HDAC1ROCK2ROCK1NPC1 | |
| SCHEMBL30424839 | 0.84 | HDAC6 (0.42) | HDAC6GSK3BDYRK1ANAMPTHDAC1 | |
| SCHEMBL25270189 | 0.84 | HDAC6 (0.42) | HDAC6GSK3BDYRK1ANAMPTHDAC1 | |
| SCHEMBL25216024 | 0.83 | HDAC6 (0.44) | HDAC6GSK3BDYRK1AHDAC1ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286970-A1 | NOVEL OXADIAZOLE-BASED SELECTIVE HDAC6 INHIBITORS | ITALFARMACO SPA (IT) | 2023-09-14 | — | — | US | claimed |
| US-20230286970-A1 | NOVEL OXADIAZOLE-BASED SELECTIVE HDAC6 INHIBITORS | ITALFARMACO SPA (IT) | 2023-09-14 | — | — | US | disclosed |
| EP-4192830-A1 | 2-(4-((5-(BENZO[B]THIOPHEN-3-YL)-1H-TETRAZOL-1-YL)METHYL)PHENYL)-5-(DIFLUOROMETHYL)-1,3,4-OXADIAZOLE DERIVATIVES AND SIMILAR COMPOUNDS AS SELECTIVE INHIBITORS OF HISTONE DEACETYLASE 6 (HDAC6) FOR USE IN TREATING E.G. PERIPHERAL NEUROPATHY | Italfarmaco SpA (IT) | 2023-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230286970-A1 | NOVEL OXADIAZOLE-BASED SELECTIVE HDAC6 INHIBITORS | HDAC6, HDAC1, HDAC3 | HDAC6 1/4885GSK3B 116/4885DYRK1A 2513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.